Campaign Funds and Pharmacy Bills Linked in Past Vote
Wisconsin residents may consider how political donations to Rep. Bryan Steil align with legislative outcomes on drug pricing.
Updated on Sept. 25, 2026 in Diabetes
Live Poll
Do you believe campaign donations from lobbyists influence the voting decisions of members of Congress?
Records show Rep. Bryan Steil accepted campaign funds from pharmaceutical lobbyists shortly before casting votes on major drug pricing legislation. These legislative actions included voting on provisions impacting Medicare drug price negotiations.
Why it matters
Legislative decisions regarding pharmaceutical costs directly influence medication affordability for patients across Wisconsin. Understanding these financial ties provides context for how policies affecting insulin and orphan drug pricing are shaped in Congress.
Official records indicate Rep. Bryan Steil accepted roughly $220,000 in pharmaceutical industry contributions. These filings show specific donations from lobbyists shortly before votes on bills affecting Medicare negotiations and insulin pricing, though the impact of these funds remains debated.
The players
Bryan Steil
A U.S. Representative who has accepted campaign funding from the pharmaceutical industry and voted on relevant drug pricing legislation.
Dan Todd
A lobbyist representing pharmaceutical interests who contributed funds to Rep. Bryan Steil.
Robert Wood
A lobbyist associated with pharmaceutical industry advocacy who provided campaign funds to Rep. Bryan Steil.
The details
The pharmaceutical industry employs lobbyists to engage lawmakers on policies impacting drug pricing, including the $8.8 billion provision in the One Big Beautiful Bill. These legislative measures dictate how Medicare negotiates costs for orphan drugs and sets price caps for insulin. When representatives vote on such bills, the resulting policy changes can shift the financial burden for medications directly onto patients and insurance systems.
Timeline
March 31, 2022: Rep. Steil received a $1,500 donation and voted against the Affordable Insulin Now Act.
July 1, 2025: Rep. Steil accepted a $500 contribution from lobbyist Dan Todd.
July 3, 2025: Rep. Steil voted in favor of the One Big Beautiful Bill.
Health Landscape
The Affordable Insulin Now Act serves as a benchmark for evaluating legislative support for patient affordability. Current voting trends on pharmaceutical provisions highlight a shift in how insulin and orphan drug costs are managed within federal policy frameworks.
These legislative outcomes influence the out-of-pocket costs and insurance coverage options available for insulin and specialty medications. Patients concerned about drug affordability should track how future bills are voted on and discuss these policy impacts with their healthcare providers.
The takeaway
Legislative actions regarding pharmaceutical pricing significantly alter the landscape for patient medication costs. Residents are encouraged to monitor Congressional votes on drug price caps and discuss potential changes in access to care with their physicians.
Further reading
For more context on how legislative decisions impact medication access and costs, see our Diabetes section.
Source note: This article includes information reported by The Milwaukee Courier.
Live Poll
Do you believe campaign donations from lobbyists influence the voting decisions of members of Congress?
